SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control

Magdalene K. Montgomery, Jacqueline Bayliss, Camille Devereux, Ayenachew Bezawork-Geleta, David Roberts, Cheng Huang, Ralf B. Schittenhelm, Andrew Ryan, Scott L. Townley, Luke A. Selth, Trevor J. Biden, Gregory R. Steinberg, Dorit Samocha-Bonet, Ruth C. R. Meex, Matthew J. Watt*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number8048
Number of pages13
JournalScience Translational Medicine
Volume12
Issue number559
DOIs
Publication statusPublished - 2 Sep 2020

Keywords

  • INSULIN-RESISTANCE
  • BINDING PROTEIN
  • CREB
  • GLUCONEOGENESIS
  • TRANSCRIPTION
  • METABOLISM
  • LIVER
  • PHOSPHORYLATION
  • IDENTIFICATION
  • EXERCISE

Cite this

Montgomery, M. K., Bayliss, J., Devereux, C., Bezawork-Geleta, A., Roberts, D., Huang, C., Schittenhelm, R. B., Ryan, A., Townley, S. L., Selth, L. A., Biden, T. J., Steinberg, G. R., Samocha-Bonet, D., Meex, R. C. R., & Watt, M. J. (2020). SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Science Translational Medicine, 12(559), [8048]. https://doi.org/10.1126/scitranslmed.aaz8048